Demographics (2)
- age - Subject age at thearpy start (phv00328784.v1.p1)
- sex - Gender of participant (phv00328785.v1.p1)
Disease Events (3)
- AFFECTION_STATUS - Subject response to anti-PD1 therapy (phv00328778.v1.p1)
- os - Overall Survival (phv00328792.v1.p1)
- pfs - Progression Free Survival (phv00328791.v1.p1)
Medications (1)
- prior_ipilimumab - Prior therapy with ipilimumab (phv00328787.v1.p1)
Other (18)
- ANALYTE_TYPE - Analyte Type (phv00328794.v1.p1)
- biopsy_setting - Stage at which biopsy was taken (phv00328789.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00328776.v1.p1)
- histologic_subtype - Histologic Subtypeof Desmoplastic melanoma (phv00328783.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00328796.v1.p1)
- IS_TUMOR - Tumor status (phv00328795.v1.p1)
- orr - Overall Response by RECIST 1.1 criteria (phv00328790.v1.p1)
- PRESERVATION_TYPE - Sample preservation method (phv00328797.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00328793.v1.p1)
- SAMPLE_ID - Sample ID (phv00328780.v1.p1)
- SAMPLE_USE - Sample use. Seq_DNA_SNP_MAF_Ind: Sample(s) were used to generate aggregate mutation annotation file (.maf) with individual SNP genotypes; Seq_DNA_WholeExome: Whole exome sequencing (phv00328781.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00328798.v1.p1)
- stage - TNM Staging at therapy start (phv00328786.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00328782.v1.p1)
- SUBJECT_ID - Subject ID (phv00328775.v1.p1)
- SUBJECT_ID - Subject ID (phv00328779.v1.p1)
- SUBJECT_SOURCE - Source repository where subjects originate (phv00328777.v1.p1)
- treatment - Therapy (phv00328788.v1.p1)